Exemestane With or Without ATN-224 in Treating Postmenopausal Women With Recurrent or Advanced Breast Cancer
Status:
Terminated
Trial end date:
2009-03-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Exemestane may stop the growth of tumor cells by blocking some of the enzymes
needed for cell growth. ATN-224 may stop the growth of breast cancer by blocking blood flow
to the tumor. It is not yet known whether giving exemestane together with ATN-224 is more
effective than giving exemestane alone in treating patients with recurrent or advanced breast
cancer.
PURPOSE: This randomized phase II trial is studying the side effects of exemestane given
together with or without ATN-224 and to see how well it works in treating postmenopausal
women with recurrent or advanced breast cancer.